新发病的糖尿病视网膜病变与类似葡萄糖-1受体激动剂:一个病例报告
Jennifer Ko1, Yaseman Jahromi2
1Chapman University School of Pharmacy, 9401 Jeronimo Rd, Irvine, CA 92618.
概括
类似葡萄糖-1受体激活剂 (GLP-1RA) 可能加速糖尿病视网膜病变 (DR) 在2型糖尿病 (T2D) 患者的进展. 在这些情况下,切换为口服赛马格卢提德可能会改善DR和糖尿病黄斑 (DME).
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变 (DR) 是患有2型糖尿病 (T2D) 的成年人视力损失的主要原因.
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 常用于T2D管理.
- 新出现的证据表明GLP-1RA使用和加速DR之间存在潜在联系,尽管发现是混合的.
研究的目的:
- 报告关于在开始GLP-1RA治疗后经历了新发病和恶化的DR的T2D患者管理的临床决策.
- 探索不同GLP-1RA配方对DR进展的潜在影响.
主要方法:
- 一个43岁的女性患有T2D和肥胖的病例报告.
- 患者最初接受了注射GLP-1RA (exenatide ER,dulaglutide) 药物,后来接受了皮下注射的semaglutide.
- 在检测出糖尿病黄斑 (DME) 时,治疗被切换为口服赛马格卢提德.
主要成果:
- 患者在19个月的注射GLP-1RA后发展出轻度的非增殖性DR.
- 糖尿病黄斑 (DME) 发生在切换到皮下塞马格卢提德后两个月.
- 在切换到口服赛马格卢提德8个月后,DR有所改善,DME显著消失.
结论:
- 即使在受控的T2D中,GLP-1RA疗法也可能有助于DR进展.
- 切换到具有潜在较低DR风险的GLP-1RA药物,如口服赛马格卢提德,可能是有益的.
- 需要进一步的研究来澄清GLP-1RA类对DR的风险,并制定管理准则.
相关概念视频
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Hypoglycemia and Glucagon
349
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
349
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K


